Clinical Trial Update: An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections [Phase 3]

View source ↗

Summary

Open-label Phase III trial evaluating voriconazole for invasive fungal infections has completed, assessing efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Fungal Infection

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Mycoses | Phase 3 | Status: COMPLETED